<DOC>
	<DOC>NCT00696891</DOC>
	<brief_summary>This study is conducted to compare the immunogenicity, reactogenicity and safety of Engerix™-B and HBV-MPL vaccine against hepatitis B infection in an elderly population</brief_summary>
	<brief_title>Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults</brief_title>
	<detailed_description>At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age: 50 to 70 years old. Good physical condition as established by clinical examination and history taking at the time of entry. Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. Written informed consent obtained from the subjects Positive at screening for antiHBV antibodies. Elevated serum liver enzymes History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease. Any acute disease at the moment of entry. Chronic alcohol consumption. Hepatomegaly, right upper quadrant abdominal pain or tenderness. Any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study. History of allergic disease likely to be stimulated by any component of the vaccine. Simultaneous participation in any other clinical trial. Previous vaccination with a recombinant hepatitis B vaccine. Previous vaccination with an MPL containing vaccine. Administration of immunoglobulins in the past 6 months and during the whole study period Vaccination one week before and one week after each dose of the study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Adjuvanted hepatitis B vaccine, hepatitis B, Engerix™-B</keyword>
</DOC>